Celsion gets OK for Phase III cancer-drug trial in four countries

Celsion (CLSN) receives regulatory clearance to start a Phase III study of its ThermoDox treatment for primary liver cancer in Taiwan, Hong Kong, South Korea and Canada.

The company has also applied for approval to conduct trials in the Philippines, Thailand, China and Europe

Celsion has already received FDA clearance for the study, whose primary endpoint is overall survival.

The company expects to enroll 550 patients globally at up to 100 sites. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs